Found 14 articles
Peanut allergy is the most common food allergy in children and that number has been rising – peanut allergy incidence increased 21 percent from 2010 to 2017. Almost 2.5 percent of children in the US are thought to have a peanut allergy, according to the American College of Allergy, Asthma, and Im...
AllerGenis announced the publication of a peer-reviewed study entitled, "Accurate and Reproducible Diagnosis of Peanut Allergy Using Epitope Mapping." Conducted by leading global experts in pediatric allergy and immunology from the Icahn School of Medicine at Mount Sinai, Stanford University and Kings College, the study found the AllerGenis peanut diagnostic blood test demonstrates accuracy significantly and statistically superior to all other established diagnostic tests.
Ukko Secures $40 Million in Series B Funding Led by Leaps by Bayer to Overcome Food Allergies and Sensitivities
Top industry leaders and venture firms unite behind Ukko's efforts to eliminate the world's most prevalent food allergies and sensitivities, including peanuts and gluten
Intrommune to Participate in BIO @ JPM During “J.P. Morgan Week 2021”Virtual Bio-Partnering Platform Connects Biotech Leaders with Investors; Partners
Intrommune Therapeutics , a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, will participate in BIO’s one-on-one virtual partnering meeting during the 39 th annual J.P. Morgan Healthcare Conference taking place January 11 – 14, 2021. The BIO One-on-One Partnering @ JPM platform enables partners and investors to schedule virtual video meetings with Intrommune executives. To
DBV Technologies aims to fill the peanut allergy treatment gap, especially for highly allergic children, with their low dose epicutaneous immunotherapy (EPIT) patch Viaskin™ Peanut.
In its CRL, the FDA identified concerns regarding the impact of patch-site adhesion on efficacy and indicated the need for patch modifications.
AllerGenis Begins Testing Patient Samples for Peanut Allergy Using Proprietary Epitope Mapping Technology
AllerGenis LLC, a data-driven precision diagnostics company focused on food allergies, today announced the onset of operations at its Hatfield facility to test patient samples using its VeriMAP TM Peanut Diagnostic, a diagnostic solution for patients with peanut allergies. AllerGenis received full certification under Clinical Laboratory Improvement Amendments of 1988 (CLIA) to perform its high complexity clinical l
New Two-Year PALFORZIA™ Data Show On-going Safety and Efficacy and Continued Immunomodulation in Patients with Peanut Allergy
New Two-Year PALFORZIA™ Data Show On-going Safety and Efficacy and Continued Immunomodulation in Patients with Peanut Allergy — After Two Years of Daily Treatment, More Than 80% of Patients Were Successfully Desensitized to 2000 mg Peanut Protein or Equivalent of About 14 Peanut Kernels— — Majority of Patients Treated Daily Also Reported Lower Rates of Adverse Events and Showed Higher Rates of Desensitization Compared to Non-Daily Dosing Groups —
Aimmune Announces First U.S. Patients Are Being Treated with Newly-Approved PALFORZIA™, the First Treatment for Peanut Allergy
Aimmune Therapeutics, Inc. today announced that the first patients in the United States are being treated with PALFORZIA™ [Peanut ( Arachis hypogaea ) Allergen Powder-dnfp], the first approved treatment for peanut allergy. Following the release of the medication lots by the U.S. Food an
DBV announced positive topline results from its Phase III PEPITES trial evaluating the long-term efficacy and safety of investigational Viaskin Peanut in peanut-allergic children aged 4 to 11 years.
FARE said the biomarker research project, which will be conducted at Janssen’s World Without Disease Accelerator, “has the potential to make a real and significant impact for the 32 million Americans living with food allergies.”
AR101 is an investigational, peanut-derived, biologic drug candidate for oral immunotherapy in patients with peanut allergy. It delivers a daily dose of peanut protein with a consistent protein profile.
Aimmune to Present New Data on Safety and Efficacy of AR101, Clinical Practice Implementation of Oral Immunotherapy, Quality of Life and Other Related Studies at ACAAI 2019
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced it will present new data on the safety and efficacy of the company’s lead investigational candidate, AR101 (trade name Palforzia™), at the American College of Asthma, Allergy and Immunology (ACAAI) Annual Scientific Meeting, taking place November 7-11, 2019, in Houston
Aimmune’s peanut allergy treatment is one-step closer to approval following strong support from the Allergenic Products Advisory Committee, which overwhelmingly recommended approval of Palforzia, the proposed trade name of the investigational oral treatment, AR101.